| EX1337 INFLIXIMAB; ANTI-TNF BLOCKER |
| Specimen: |
3 mL (2 mL min.) serum from 1 SST. Ship refrigerated or frozen. |
| Stability: |
| Room |
Refrigerated |
Frozen |
| 4 hrs |
7 days |
14 days |
|
| Method: |
EIA |
| Comment: |
If the trough concentration of the drug is low, it is suggested to measure Infliximab antibody levels. |
| Report: |
Contact us to know the TAT. |
| Usage: |
Infliximab is a chimeric immunoglobulin (IgG 1 Kappa) targeting TNF-alpha molecules. It is an FDA-approved therapeutic agent for multiple inflammatory conditions like Crohn’s Disease, Ulcerative Colitis, Psoriasis, Ankylosing Spondylitis, and Rheumatoid Arthritis. The trough concentration of these drugs can vary due to disease severity, phenotype, degree of inflammation, use of immunomodulatory, patient gender, and body mass index, as well as variability in drug clearance through immune and non-immune mediated mechanisms. Several studies have demonstrated that infliximab quantitation in the setting of loss of response to therapy can aid in patient management, as trough concentrations defined as therapeutic have been associated with superior clinical response and improved prognosis. |
| Doctor Specialty: |
Gastroenterologist, Rheumatologist |
| Disease: |
Disorders of Gastroenterological Tract, Inflammation |
| Components: |
|
| Courier Charges: |
Included with MRP. |
| Home Collection: |
Available (*T&C Apply) |
| Department: |
IMMUNOASSAY |
| Pre Test Information: |
Ideal sampling time: Just before the next dose (trough levels). A duly filled Test Send Out Consent Form is mandatory. |
Reviews
There are no reviews yet.